Delta variant shows 8-fold sensitivity to vaccine-driven antibodies: Study

This is based on a recent study on the B.1.617.2 Delta variant on over 100 healthcare workers (HCWs) across three centres in Delhi, including Sir Ganga Ram Hospital.

Coronavirus mutation, coronavirus strain, coronavirus variant
Photo: Shutterstock
IANS New Delhi
4 min read Last Updated : Jul 05 2021 | 6:03 PM IST

The Delta variant of Covid-19 virus shows eight-fold approximately reduced sensitivity to vaccine elicited antibodies compared to the Wuhan strain, revealed a recent study on the B.1.617.2 Delta variant on over 100 healthcare workers (HCWs) across three centres in Delhi, including Sir Ganga Ram Hospital.

As per the study, the variant is less sensitive to neutralising antibodies from recovered individuals, with higher replication efficiency as compared to the Alpha variant. The study is available online as a non-peer reviewed preprint version in Research Square, an expanded set of services and tools for expert research assistance.

It is a collaborative study involving scientists from the Cambridge Institute of Therapeutic Immunology and Infectious Disease.

In an analysis of vaccine breakthrough in over 100 HCWs, a statement issued by Sir Ganga Ram Hospital based on the outcome of the study said that across three centers in India, the B.1.617.2 Delta variant not only dominates vaccine-breakthrough infections with higher respiratory viral loads compared to non-Delta infections (Ct value of 16.5 versus19), but also generates greater transmission between fully vaccinated HCWs as compared to the other variants B.1.1.7 or B.1.617.1

The Delta variant, first detected in India, is now being reported in nearly 100 countries, which is "likely an underestimate" and the highly transmissible strain is expected to rapidly outcompete other variants and become dominant globally over the coming months, the WHO had said last week.

According to Chand Wattal, Chairperson, Institute of Clinical Microbiology and Immunology, Sir Ganga Ram Hospital, "From this study it appears that we have to go miles before we sleep in case of the Covid-19 pandemic. These mutations are bound to happen if we lower our guard and allow ourselves to fall prey to this virus, giving it an opportunity to multiply and achieve better fitness with our Covid inappropriate behaviour. This is a straight eye opener for the fully vaccinated people that you cannot lower your guard in the name of vaccination. The virus is still looking of its prey."

Wattal said the mutant has come back with enhanced spike proteins for attachment to the lung epithelial cells which has provided it much higher capacity to infect many more people than the Wuhan strain.

"These combined epidemiological and in vitro data indicate that the dominance of the Delta variant in India has been most likely driven by a combination of evasion of neutralising antibodies in previously infected individuals and increased virus infectivity resulting in the second wave.

"While severe disease in fully vaccinated HCWs was rare, breakthrough transmission clusters in hospitals associated with the Delta variant are concerning and indicate that infection control measures need to continue in the post-vaccination era.

"The B.1.167.2 Delta variant appears more transmissible than B.1.1.7 in the UK based on recent data and the dominance of new infections by this variant," Wattal said.

In the absence of published data on the transmissibility of the Delta variant, the study predicts that this variant will have a transmission advantage relative to Wuhan-1 with 'D614G' in individuals with pre-existing immunity from vaccine and natural infection as well as in settings where there is low vaccine coverage and low prior exposure.

Lower protection against B.1.351, the variant with least sensitivity to neutralising antibodies, has been demonstrated for at least three vaccines. However, progression to severe disease and death was low in all the studies.

Therefore, extensive vaccination will likely protect against moderate to severe disease and will reduce hospitalisation due to the Delta variant.

--IANS

rak/arm

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Jul 05 2021 | 6:03 PM IST

Next Story